EUVIMEDEUVIMED entdecken
Open Access

MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways

Shouhui Yang iD, Wei Tang, Azadeh Azizian, Jochen Gaedcke, Yuuki Ohara, Helen Cawley, Nader Hanna, Michael Ghadimi, Trisha Lal, Subrata Sen, Chad J Creighton iD, Jianjun Gao und 3 weitere

Carcinogenesis · 12.08.2024 · 45 (8) · 582-594

DOI: 10.1093/carcin/bgae025 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carcinogenesis, online erschienen am 17.04.2024. Verfasst von Shouhui Yang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, …. Hauptthemen laut MEDLINE: Macrophage Migration-Inhibitory Factors, Pancreatic Neoplasms, Glucose, Intramolecular Oxidoreductases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammation and aberrant cellular metabolism are widely recognized as hallmarks of cancer. In pancreatic ductal adenocarcinoma (PDAC), inflammatory signaling and metabolic reprogramming are tightly interwoven, playing pivotal roles in the pathogenesis and progression of the disease. However, the regulatory functions of inflammatory mediators in metabolic reprogramming in pancreatic cancer have not been fully explored. Earlier, we demonstrated that pro-inflammatory mediator macrophage migration inhibitory factor (MIF) enhances disease progression by inhibiting its downstream transcriptional factor nuclear receptor subfamily 3 group C member 2 (NR3C2). Here, we provide evidence that MIF and NR3C2 interactively regulate metabolic reprogramming, resulting in MIF-induced cancer growth and progression in PDAC. MIF positively correlates with the HK1 (hexokinase 1), HK2 (hexokinase 2) and LDHA (lactate dehydrogenase) expression and increased pyruvate and lactate production in PDAC patients. Additionally, MIF augments glucose uptake and lactate efflux by upregulating HK1, HK2 and LDHA expression in pancreatic cancer cells in vitro and in mouse models of PDAC. Conversely, a reduction in HK1, HK2 and LDHA expression is observed in tumors with high NR3C2 expression in PDAC patients. NR3C2 suppresses HK1, HK2 and LDHA expression, thereby inhibiting glucose uptake and lactate efflux in pancreatic cancer. Mechanistically, MIF-mediated regulation of glycolytic metabolism involves the activation of the mitogen-activated protein kinase–ERK signaling pathway, whereas NR3C2 interacts with the activator protein 1 to regulate glycolysis. Our findings reveal an interactive role of the MIF/NR3C2 axis in regulating glucose metabolism supporting tumor growth and progression and may be a potential target for designing novel approaches for improving disease outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Macrophage Migration-Inhibitory FactorsPancreatic NeoplasmsGlucoseIntramolecular OxidoreductasesCarcinoma, Pancreatic DuctalTranscription Factor AP-1HumansAnimalsMiceCell Line, TumorMAP Kinase Signaling SystemGene Expression Regulation, NeoplasticHexokinaseCell ProliferationSignal TransductionMetabolic Reprogramming

Substanzen

Macrophage Migration-Inhibitory FactorsGlucoseIntramolecular OxidoreductasesMIF protein, humanTranscription Factor AP-1Hexokinase

Autor:innen und Institutionen

  • Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  • Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA.
  • Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Göttingen, Germany.
  • Division of Surgical Oncology, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Howard University College of Medicine, Washington, DC, USA.
  • Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

ORCID-Profile: Shouhui Yang, Chad J Creighton, Stefan Ambs, Perwez Hussain

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Yang, S., Tang, W., Azizian, A., Gaedcke, J., Ohara, Y., Cawley, H., Hanna, N., Ghadimi, M., Lal, T., Sen, S., Creighton, C. J., Gao, J., Putluri, N., Ambs, S., & Hussain, P. (2024). MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways. Carcinogenesis, 45(8), 582-594. https://doi.org/10.1093/carcin/bgae025

Vancouver

Yang S, Tang W, Azizian A, Gaedcke J, Ohara Y, Cawley H, et al. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways. Carcinogenesis. 2024;45(8):582-594. doi:10.1093/carcin/bgae025

BibTeX
@article{Yang2024,
  author = {Yang, Shouhui and Tang, Wei and Azizian, Azadeh and Gaedcke, Jochen and Ohara, Yuuki and Cawley, Helen and Hanna, Nader and Ghadimi, Michael and Lal, Trisha and Sen, Subrata and Creighton, Chad J and Gao, Jianjun and Putluri, Nagireddy and Ambs, Stefan and Hussain, Perwez},
  title = {MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways},
  journal = {Carcinogenesis},
  year = {2024},
  volume = {45},
  number = {8},
  pages = {582--594},
  doi = {10.1093/carcin/bgae025}
}
Kostenlos starten →